There is no news to report at this time.
Walgreen, Omnicare trade assets (Investor's Business Daily) Investor's Business Daily - The drugstore giant said it will buy the home infusion unit of Omnicare in exchange for its long-term care pharmacy business. Terms were not disclosed. Separately, Walgreen said its Aug. same-store sales rose 2.1%, below views. Generic drug introductions and a decrease in customer traffic hurt sales. Shares were unchanged.
Orexigen, Takeda in $1 bil deal (Investor's Business Daily) Investor's Business Daily - Drugmaker Orexigen Therapeutics (NMS:OREX) jumped 18.3% to 5.43 after it sold the North American marketing rights for its experimental weight-loss drug to Japan's Takeda Pharmaceutical for more than $1 bil. Orexigen is one of three U.S. companies trying to get approval for the first new diet drug in a decade. The FDA is expected to make a decision on the drug, Contrave, by Jan. 31.
Orexigen signs $1 billion obesity drug deal (AP) AP - Shares of Orexigen Therapeutics Inc. surged Thursday after the drugmaker said it signed a $1 billion co-development agreement for its experimental obesity drug Contrave with Takeda Pharmaceuticals.
Eli Lilly (Investor's Business Daily) Investor's Business Daily - , a drugmaker, said a federal appeals court upheld patents protecting its osteoporosis treatment Evista. The court also upheld a decision invalidating portions of its patents. Shares fell 1.8%.
Pfizer (Investor's Business Daily) Investor's Business Daily - will buy privately held FoldRx Pharma, a developer of treatments for diseases caused by protein misfolding, for an undisclosed amount. Shares rose 2.3%.
Court denies Scrushy's request for release on bond (AP) AP - A federal appeals court has denied former HealthSouth CEO Richard Scrushy's request to be released from prison on bond.
Pharmacy measure in ND Supreme Court's hands (AP) AP - Supporters of a voter initiative that could help bring cheaper prescription drugs to North Dakota are hoping a legal technicality won't keep them from getting the issue placed on the ballot.
Ex-hedge fund manager charged with insider trading (Reuters) Reuters - A former hedge fund manager has been accused by a U.S. regulator of illegal insider trading in MedImmune Inc securities prior to the acquisition of the pharmaceutical company by Britain's AstraZeneca Plc.
Pfizer buying FoldRx for undisclosed amount (AP) AP - Pfizer Inc. said Wednesday it will buy privately held FoldRx Pharmaceuticals Incl. for an undisclosed amount, expanding its pipeline of potential products.
Bristol, Bayer drugs effective (Investor's Business Daily) Investor's Business Daily - The drugmakers' rival anti-clotting drugs both proved safe and effective in clinical trials. Bayer's (OTCBB:BAYRY.ob - News) Xarelto helped dissolve potentially deadly clots in the legs and prevented new ones. Bristol-Myers Squibb's apixaban, commercialized with help from with Pfizer , reduced the risk of stroke by 52% vs. aspirin, researchers said.
Bayer and Bristol's rival clot drugs both impress (Reuters) Reuters - Rival anti-clotting drugs from Bayer (BAYGn.DE) and Bristol-Myers Squibb both impressed in clinical trials, keeping them firmly in the race to displace the old, problematic heart drug warfarin.
Genzyme board rejects Sanofi bid (AFP)
AFP - The board of directors at US biotechnology firm Genzyme has unanimously rejected an 18.5-billion-dollar takeover offer from French pharmaceutical giant Sanofi-Aventis, Genzyme said Monday.
Sanofi-Aventis makes 18.5 bln dollar bid for US Genzyme (AFP)
AFP - French pharmaceutical group Sanofi-Aventis unveiled Sunday an 18.5 billion dollar (14.5 billion euro) offer for US biotechnology firm Genzyme, hinting it may launch a hostile bid.
Roche says no decision on job cuts this week (Reuters) Reuters - Swiss drugmaker Roche Holding AG said on Sunday it would not make any decision on job cuts this week, after Swiss newspaper Sonntag reported it could be about to cut thousands of positions.
Lilly wins longer halt on generics (Investor's Business Daily) Investor's Business Daily - The drugmaker edged up after a federal appeals court extended a temporary order blocking 10 companies from selling generic versions of the company's Strattera attention deficit disorder drug. Eli Lilly had filed an appeal after a lower court ruled Lilly's patent invalid. The patent had been set to expire in '17. Generic-drug makers affected by the order include Mylan (NMS:MYL) and Teva Pharmaceutical Industries (NMS:TEVA). Lilly rose 0.7% to 34.20.
Endo Pharmaceuticals Looks For Acquisitions (Investor's Business Daily) Investor's Business Daily - Looking at all of its recent acquisitions, you might think Endo Pharmaceutical's (NMS:ENDP) business model echoes another firm's. One like Johnson & Johnson's .
FDA denies accelerated approval for cancer drug (AP) AP - Federal regulators have ruled that a potential breast cancer treatment from ImmunoGen failed to meet the standard for accelerated approval, the company said Friday.
Chindex sells $14 million in stock to Fosun Pharma (AP) AP - Chindex International sold $14 million of its shares to another Chinese medical concern as part of its plans to form a new joint venture, the company said Friday.
Calif. OKs Wellpoint rate hike (Investor's Business Daily) Investor's Business Daily - Calif. regulators accepted rate hikes averaging 14% for individual Anthem Blue Cross health insurance customers. The regulators also approved a nearly 19% increase for Blue Shield of Calif. Anthem, a unit of WellPoint , had requested a boost that would have raised rates an average of 25% and as much as 39% for some customers. Public outrage and gov't scrutiny halted a larger increase.
Schweitzer cooking up new plan for cheap drugs (AP) AP - Gov. Brian Schweitzer, cooking up a new plan to get cheaper prescription drugs for state residents, said he wants to let every Montanan get discounted medicine through Medicaid.
Loaded at: 9/4/2010 10:06:30 AM